TrippBio

Neutral
BETA

TrippBio is developing a new, therapeutic application of an FDA-approved drug with a high probability to be proven safe and efficacious in the treatment and prevention of the SARS-CoV-2 virus that causes COVID-19.

Analytics

Raised to Date: $154,248

Aggregate Commitments $
Platform

Netcapital

Start Date

09/16/2020

Close Date

01/29/2021

Min. Goal

$10,000

Max. Goal

$1,070,000

Min. Investment

$100

Security Type

Equity - Common

Funding Type

RegCF / RegD 506(C)

Series

Pre-Seed

Pre-Money Valuation

$5,255,840

Weekly Commitments $
Status

Active

Reporting Date

01/17/2021

Days Remaining

10

% of Min. Goal

1,542%

% of Max. Goal

14%

Likelihood of Max
Avg. Daily Raise

$1,254

Momentum
Location

Jacksonville, Florida

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Distribution Model

B2B

Margin

Medium

Capital Intensity

High

Business Type

Growth

TrippBio, with a post-money valuation of $7.1 million, is raising funds on NetCapital. The company is developing a new therapeutic application of an FDA-approved drug for the treatment and prevention of the SARS-CoV-2 virus. The company believes that the drug TD213 is capable of preventing the host cell from assembling the virus that causes COVID-19. Billy Meadow and Richard Still founded TrippBio in May 2020. The current round of crowdfunding has a minimum raise of $10,000 and a maximum raise of $1,070,000, and the funds will be used for initial clinical trial, development and manufacturing of TD213, marketing and advertising, professional services, and ramp-up clinical trial. TrippBio is well-positioned to help the world combat COVID-19 and other infectious diseases.

Ratings

last updated 01/19/2021

Ratings Platform - Beta Trial

Our new ratings and analytics platform is currently in Beta. To gain access to the Beta platform features, upgrade to a Pro paid account and accept the Beta terms on any page.

For a limited time, use coupon code "TRYMERLIN20" for a free 20 day trial of Kingscrowd Pro and Merlin Beta. Your paid subscription will activate at the end of 20 days. Cancel anytime.
Other Deals

Millennial Fertility Co. on NetCapital

The Millennial Fertility Co. team has been selected as a “Deal to Watch” by KingsCrowd. This distinction is…

Crowd
Biopact on Equifund CFP

Biopact has been selected as a “Deal to Watch” by KingsCrowd. This distinction is reserved for deals selected…

Crowd
Neurotez Inc. on NetCapital

Neurotez has been selected as a “Deal To Watch” by KingsCrowd. This distinction is reserved for deals selected…

Crowd
Create your first portfolio
WELCOME TO YOUR OWN INVESTMENTS PORTFOLIO ON KINGSCROWD.

Now you can track all of your startup investments in one place utilizing our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
Add TrippBio on NetCapital
Follow company
Follow TrippBio on NetCapital